Diyaliz Tedavisi Uygulanan ve Uygulanmayan Kronik Böbrek Yetmezlikli Hastalarda Protein Oksidasyon Ürünlerinin Değerlendirilmesi

Öz

DOI: 10.26650/experimed.2018.430561

Amaç: Bu çalışmada replasman tedavisi alan ve almayan kronik böbrek yetmezliği (KBY) hastalarının kan protein oksidasyon ürünlerinin düzeylerini değerlendirmek ve hasta kişiler ile sağlıklı kişileri karşılaştırmak için kontrol grubu (n=35) ve hasta grupları oluşturuldu.

Gereç ve Yöntem: Hasta grupları replasman tedavisi almayan KBY hasta grubu (n=36), hemodiyaliz (HD) tedavisi gören hasta grubu (n=64) ve periton diyaliz (PD) tedavisi gören hasta grubu (n=21) olmak üzere şekillendirildi. Daha sonra ileri düzey okside protein ürünleri (AOPP) ve ileri glikasyon son ürünleri (AGE)’in düzeyleri bakımından bu gruplar değerlendirildi.

Bulgular: Sonuç olarak, replasman tedavisi almayan KBY hasta grubunun AGE düzeyleri haricinde, diğer tüm grupların AOPP ve AGE düzeylerinin kontrol grubuna göre artmış olduğu saptandı. İstatistiksel olarak en önemli artışın ise HD hasta grubunda olduğu tespit edildi. Grup içi değerlendirmeler sonucunda hiçbir grupta AOPP ve AGE düzeyleri arasında ilişki saptanmadı.

Sonuç: Bu sonuçlara göre KBY’nin oksidatif stresle birlikte seyrettiği, replasman tedavisi gören KBY hastalarında ve özellikle de HD tedavisi gören hastalarda oksidatif stresin çok daha şiddetli olduğu gözlemlendi. Son olarak, HD tedavisi gören gruptaki hastaların diyabet olup olmamasının sonuçları etkilemediği görüldü.

Anahtar Kelimeler

• Kronik böbrek yetmezliği,hemodiyaliz,periton diyalizi,ileri düzey okside protein ürünleri,ileri glikasyon son ürünleri

Evaluation of Protein Oxidation Products in Patients With Chronic Renal Failure Receiving Dialysis or Not

Öz

DOI: 10.26650/experimed.2018.430561

Objective: In this study, control (n=35) and groups were formed to evaluate the levels of blood protein oxidation products in patients with chronic renal failure (CRF) who did and did not receive replacement therapy and to compare the patients with healthy subjects.

Material and Method: The groups were the CRF (n=36) group that did not receive replacement therapy, patients who were undergoing hemodialysis (HD) (n=64), and patients who were undergoing peritoneal dialysis (PD) (n=21). These groups were evaluated for the production of advanced oxidation protein product (AOPP) and advanced glycated end product (AGE) levels.

Results: As results, the AOPP and AGE values of all groups increased compared to the control group, except for the AGE levels of the patients with CRF who did not receive replacement therapy. The most significant increase was found in the HD patient group. No relationship was detected between the AOPP and AGE values in any group.

Conclusion: According to these results, CRF is accompanied by oxidative stress, and the oxidative stress is much more severe in patients with CRF receiving replacement therapy, particularly in patients undergoing HD. Is unknown if the results of patients undergoing HD were affected by the presence of diabetes.

Anahtar Kelimeler

• Advanced glycated end products,advanced oxidation protein products,chronic renal failure,hemodialysis,peritoneal dialysis

Kaynakça

1. 1. Venus S, Teresa M, Rosa S, et al., Oxidative stress and cancer: an overview. Ageing Res Rev 12: 376-390, 2013.
2. 2. Cevat Yazıcı, Kader Köse: Kronik Böbrek Yetmezliğinde Oksidatif Stres ‘‘Biyomarkır’’ları: Nefroloji Dergisi 13:117-124, 2004.
3. 3. Himmerfalb J, Hakim RM: Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12: 593–598, 2003.
4. 4. Danielski M, Ikizler A, McMonagle E, et al., Linkage of Hypoalbuminemia, Inflammation, and Oxidative Stress in Patients Receiving Maintenance Hemodialysis Therapy. Am J Kidney Dis 42 (2): 286-294, 2003.
5. 5. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al., Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49:1304-1313, 1996.
6. 6. Massy ZA, Nguyen-Khoa T, Beauvais CH. Oxidative stress and chronic renal failure: markers and management. J Nephrol 15: 336-341, 2002.
7. 7. Vaziri ND. Oxidative Stress in Uremia: Nature, Mechanisms, and Potential Consequences. Semin Nephrol 24:469-473, 2004.
8. 8. Sundl I, Roob JM, Meinitzer A, et al., Antioxidant status of patients on peritoneal dialysis: Associations with inflammation and glycoxidative stress. Periton Dialysis Int 29: 89–101, 2008.

9. 9. Witowski J, Jorres A, Korybalska K, et al., Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int Suppl 84:148–151, 2003.
10. 10. Miyata T, Devuyst O, Kurokawa K, et al., Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61:375–86, 2002.
11. 11. Lameire N, Vanholder R, De Smet R. Uremic toxins and peritoneal dialysis. Kidney Int 59: 292-297, 2001.
12. 12. Selmeci L, Seres L, Antal M, et al., Advanced oxidation protein products (AOPP) for monitoring oxidative stres in critically ill patients, fast and inexpensive automated technique; Clin Chem Lab Med 43(3): 294-297, 2005.
13. 13. Kaluosova M, Skrha J, Zima T. Advanced Glycation End-Products and Advanced Oxidation Protein Products in Patients with Diabetes Mellitus. Physiol. Res. 51: 597-604, 2002.
14. 14. Toborek M, Wasik T, Drózdz M et al., Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism 41: 1229–1232, 1992.
15. 15. Epperlein MM, Nourooz‐Zadeh J, Jayasena SD et al., Nature and biological significance of free radicals generated during bicarbonate hemodialysis. J Am Soc Nephrol 9: 457–46, 1998.
16. 16. Nguyen-Khoa T, Massy ZA. De Bandt PJ, et al., Oxidative stress and hemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 16: 335-340, 2001.
17. 17. Witko-Sarsat V, Friendlander M, Nguyen-Khoa T, et al., Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532, 1998.
18. 18. Descamps-Latscha B, Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 59:108-113, 2001.
19. 19. Chen MF, Chang CL, Liou SY. Increase in resting levels of superoxide anion in the whole blood of uremic patients on chronic hemodialysis. Blood Purif; 16: 290-300, 1998.
20. 20. Ward R, Meleisin K. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol, 5: 1967-1702, 1994.
21. 21. Craddack PR, Hammerschmidt DE. Complement-mediated granulocyte activation and down-regulation during hemodialysis. ASAIO J 7: 50-56, 1984.
22. 22. Hörl HW, Riegel W, Schollmeyer P. Different complement and granulocyte activation in patient dialyzed with PMMA dialyzers. Clin Nephrol 25: 304-307, 1986.
23. 23. Stroncek DF, Keshaviah P, Craddock PR, et al., Effect of dialyzer reuse on complement activation and neutropenia in hemodialysis. J Lab Clin Med. 104: 304-311, 1984.
24. 24. Höllgren R, Venge P, Danielson BG. Neutrophil and eosinophil degranulation during hemodialysis are mediated by the dialysis membrane. Nephron 32: 329-334, 1982.
25. 25. Hörl WH, Riegel W, Steinhauer HB, et al., Granulocyte activation during hemodialysis. Clin Nephrol 26: 30-34, 1986.
26. 26. Dalle-Donne I, Rossi R, Giustarini D, et al., Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 329:23-38, 2003.
27. 27. Mimic-Oka J, Simic T, Pljesa M, et al., Oxidative modification of plasma proteins in different stages of chronic renal failure. Med Biol 8:1-5, 2001.
28. 28. Witko-Sarsat V, Nguyen-Khoa T, Jungers P, et al., Advanced oxidation protein products as a novel molecular basis of oxidative stress in uremia. Nephrol Dial Transplant 14:76-78, 1999.
29. 29. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Daial Transplant 17: 16-24, 2002.
30. 30. Köken T, Kahraman A, Serteser M, et al., Hemodiyaliz ve Oksidatif Stres. Karatepe Tıp Dergisi 5 (Ek Sayı): 9-13, 2004.
31. 31. Donate T, Herreros A, Martinez E, et al., Protein oxidative stress in dialysis patients. Adv Perit Dial 18: 15-17, 2002.
32. 32. Kumano K, Yokota S, Go M, et al., Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 8: 127-130, 1992.
33. 33. Miyata T, Sugiyama S, Saito A, et al., Reactive carbonyl compounds related uremic toxicity (carbonyl stress). Kidney Int 59: 25-31,2001.
34. 34. Himmelfarb J, Mc Monagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 58: 2571-2578, 2000.
35. 35. Kalousov M, Krha J, Zima T. Advanced Glycation End-Products and Advanced Oxidation Protein Products in Patients with Diabetes Mellitus. Physiol. Res. 51: 597-604, 2002.
36. 36. Kalousov M, Krha J, Tesar V, et al., Advanced Glycation End Products and Advanced Oxidation Protein Products in Hemodialyzed Patients. Blood Purif 20:531–536, 2002.
37. 37. Matteucci E, Biasci E, Giampietro O. Advanced oxidation protein products in plasma: stability during storage and correlation with other clinical characteistics. Acta Diabetol 38: 187-189, 2001.
38. 38. Witko-Sarsat V, Gausson V, Descamps-Latscha B. Are advanced oxidation protein products potential uremic toxins? Kidney Int 63:11-14, 2003.